Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
β-lactamase Inhibitor
Clavulanate potassium is a potent β-lactamase inhibitor that enhances the effectiveness of β-lactam antibiotics by inhibiting bacterial enzyme activity. It is primarily used in research to study antimicrobial resistance mechanisms and to evaluate the synergy of antibiotic combinations. Clavulanate potassium is essential in elucidating bacterial adaptations and informing therapeutic strategies against resistant organisms. -
β-lactamase Inhibitor
Clavulanate lithium is a potent β-lactamase inhibitor that enhances the efficacy of β-lactam antibiotics by inhibiting bacterial enzymes responsible for antibiotic resistance. Its ability to combat antibiotic resistance makes it invaluable in research focused on understanding and overcoming treatment failures caused by resistant pathogens. Clavulanate lithium is commonly used in studies investigating the mechanisms of resistance and in the development of novel therapeutics. -
Bacterial Inhibitor
Flomoxef sodium is an oxacephem antibiotic that primarily targets bacterial ribosomes, inhibiting protein synthesis. It exhibits potent activity against a range of Gram-positive bacteria, making it suitable for research in antimicrobial resistance and bacterial infections. Flomoxef sodium can be utilized in studies exploring antibiotic efficacy and drug resistance mechanisms. -
Bacterial Inhibitor
Virginiamycin S1 is a cyclic hexadepsipeptide antibiotic that inhibits bacterial protein synthesis by targeting aminoacyl-tRNA binding and peptide bond formation. As a type B compound in the streptogramin family, it exhibits potent bactericidal activity against a diverse array of Gram-positive bacteria. Virginiamycin S1, particularly in combination with virginiamycin M1, is valuable in research focused on overcoming multidrug-resistant bacterial infections. Its application is relevant in fields such as microbiology and pharmacology, particularly in the study of antibiotic efficacy and resistance mechanisms. -
Antitumor Antibiotic/AdoHcy hydrolase Inhibitor
Neplanocin A is an antitumor antibiotic that functions as an irreversible inhibitor of AdoHcy hydrolase, with a Ki of 8.39 nM. It exhibits significant antitumor activity against murine L1210 leukemia cells and also demonstrates antiviral properties, notably against the vaccinia virus. This compound is isolated from the marine-derived organism Ampulariella regularis, making it a valuable reagent for research in cancer therapeutics and virology. -
Bacterial Inhibitor
PNU-105368 is an antibacterial compound that serves as a metabolite of linezolid. It demonstrates efficacy in inhibiting bacterial growth and is primarily excreted via the kidneys and feces. This compound is relevant for research focusing on bacterial resistance and the pharmacokinetics of oxazolidinones. -
Bacterial Inhibitor
Sisomicin is a broad-spectrum aminoglycoside antibiotic that targets bacterial ribosomes, inhibiting protein synthesis. It exhibits potent activity against Gram-positive bacteria, making it valuable in microbiological research. Sisomicin is commonly used in studies investigating bacterial resistance mechanisms and in the evaluation of antibacterial efficacy. -
Bacterial Inhibitor
Thiamphenicol-d3 is a deuterium-labeled variant of the broad-spectrum antibiotic Thiamphenicol, which targets the 50S ribosomal subunit. By binding to this subunit, it inhibits protein synthesis, exhibiting bacteriostatic activity against a wide range of Gram-negative and Gram-positive aerobic and anaerobic bacteria. This reagent is valuable for research applications involving microbiology and the study of antibiotic mechanisms. -
Bacterial Inhibitor
2,2':5',2''-Terthiophene is a heterocyclic oligomer that primarily targets bacterial inhibition. This compound exhibits significant antimicrobial activity, making it a valuable tool for studying bacterial growth and resistance mechanisms. Additionally, 2,2':5',2''-Terthiophene serves as an essential building block in the synthesis of organic semiconductor materials, particularly polythiophene, which has applications in electronic devices and sensors. -
GAK Inhibitor
GAK Inhibitor 2 is a selective inhibitor of cyclin G-associated kinase (GAK), exhibiting a potent IC50 value of 0.024 μM. This compound demonstrates significant antiviral activity, with an effective concentration (EC50) of 1.049 μM against dengue virus (DENV). GAK Inhibitor 2 is suitable for research exploring GAK's role in viral pathogenesis and therapeutic strategies against DENV. -
β-lactamase Inhibitor
Sulbactam pivoxil is a prodrug of Sulbactam, functioning primarily as a β-lactamase inhibitor. It demonstrates significant antibacterial activity by overcoming resistance mechanisms associated with β-lactam antibiotics. This compound is characterized by enhanced absorption compared to Sulbactam, leading to elevated serum concentrations following oral administration, making it a valuable tool for research on antibiotic resistance and evaluation of combination therapies. -
Bacterial Inhibitor
Moxifloxacin hydrochloride monohydrate is a potent bacterial inhibitor that targets DNA gyrase and topoisomerase IV, leading to the disruption of bacterial DNA replication and transcription. It exhibits strong efficacy against Streptococcus pneumoniae and is primarily utilized in the study of bacterial infections, including research on tuberculosis. Its oral bioavailability and broad-spectrum activity make it a valuable reagent for microbiological studies and antibiotic efficacy testing. -
Bacterial Inhibitor
Helvolic acid, also known as Fumigacin, is a natural antibiotic derived from Xylaria sp. It exhibits potent activity against Gram-positive bacteria, making it a valuable tool for investigating bacterial inhibition. This compound can be utilized in microbiological studies to explore mechanisms of antibiotic action and resistance. -
HIV-1 Inhibitor
Formycin A is a purine nucleoside antibiotic that acts as a potent inhibitor of human immunodeficiency virus type 1 (HIV-1), exhibiting an EC50 of 10 μM. This compound demonstrates notable antiviral and antitumor activities, making it a valuable tool for research in virology and cancer biology. Its efficacy against HIV-1 makes it a relevant candidate for studies aimed at developing antiviral therapies. -
Calcium Ionophore Antibiotic, Methanogenic Bacteria Inhibitor
Chlortetracycline is a calcium ionophore antibiotic that primarily targets bacterial protein synthesis by inhibiting the binding of aminoacyl-tRNA to ribosomes. This compound demonstrates potent bactericidal activity and serves as a selective inhibitor of methanogenic bacteria. Chlortetracycline is widely utilized in research applications involving antibiotic resistance studies and metabolic pathway investigations in anaerobic organisms. -
Bacterial Inhibitor
Cefamandole is a semi-synthetic second-generation cephalosporin antibiotic that functions as a bacterial inhibitor by disrupting cell wall synthesis. It exhibits broad-spectrum antimicrobial activity against various Gram-positive cocci and several Gram-negative bacilli, while maintaining resistance to hydrolysis by certain β-lactamases. Although effective in many contexts, it shows limited efficacy against species such as Pseudomonas, Proteus vulgaris, and Providencia stuartii. Cefamandole is primarily excreted in the urine in its active form and is utilized in research applications focused on bacterial infections, although its penetration across the blood-brain barrier is minimal. -
Bacterial Inhibitor
Cinnamycin is a tetracyclic peptide antibiotic that specifically targets phosphatidylethanolamine (PE). Its primary mechanism involves disrupting bacterial membrane integrity, leading to inhibition of growth in Gram-positive bacteria. Cinnamycin is commonly utilized in microbiological research to study antibiotic resistance and bacterial membrane dynamics. -
Bacterial Inhibitor
Aureothricin is a dithiolopyrrolone (DTP) antibiotic with a primary mechanism of inhibiting bacterial growth. It demonstrates broad-spectrum antibiotic activity and has the ability to impede the adhesion of human umbilical vein endothelial cells (HUVECs) to vitronectin. This compound is valuable for research applications focused on bacterial inhibition and the modulation of cell adhesion processes. -
Bacterial Inhibitor
Flomoxef is an oxacephem antibiotic that exerts its bactericidal effects primarily by inhibiting bacterial cell wall synthesis. It demonstrates significant activity against a range of Gram-positive bacteria. This compound is utilized in research settings to investigate antibiotic resistance mechanisms and to develop novel antibacterial agents. -
Bacterial Inhibitor
Flucloxacillin is a β-lactam antibiotic that primarily targets bacterial cell wall synthesis by inhibiting transpeptidation enzymes. It exhibits potent antibacterial activity against a variety of gram-positive and some gram-negative bacteria, making it valuable in treating infections caused by staphylococci and streptococci. This reagent is widely utilized in microbiological studies and antibiotic susceptibility testing to evaluate bacterial resistance. -
Bacterial Inhibitor
Sulfadimethoxine-d6 is a deuterated form of Sulfadimethoxine, a sulfonamide antibiotic that acts as a bacterial inhibitor by interfering with folate synthesis in pathogenic microorganisms. This reagent is primarily utilized in pharmacokinetics and metabolic studies, allowing for improved tracking of the compound in biological systems. Its deuterium labeling enhances analytical sensitivity in various applications, including drug metabolism research and isolation studies. -
Bacterial Inhibitor
Bacampicillin is a penicillin antibiotic that serves as a prodrug of ampicillin, designed to enhance oral bioavailability. It exerts its antibacterial activity through the inhibition of cell wall synthesis in susceptible bacteria. This compound is utilized primarily in microbiological research and studies targeting bacterial infections. -
SARS-CoV-2 3CL Proteas Inhibitor
SARS-CoV-2 3CLpro-IN-13 is a highly effective inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 21 nM. This compound demonstrates significant anti-coronavirus activity, making it a valuable tool for research focused on SARS-CoV-2 inhibition and antiviral drug development. It is suitable for studies investigating the biochemical mechanisms underlying coronavirus replication and the potential therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 PLpro and Mpro Inhibitor
LY1 is a selective covalent inhibitor targeting the SARS-CoV-2 proteases PLpro and Mpro, demonstrating Kd values of 1.5 μM and 2.3 μM for Mpro C145A and PLpro C111A, respectively. It exhibits potent antiviral activity with IC50 values of 0.12 μM against Mpro and 0.99 μM against PLpro. Additionally, LY1 showcases high selectivity, distinguishing itself from other kinases, human proteases, and metalloenzymes, making it a valuable tool for research into SARS-CoV-2 protease inhibition. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-86 is an inhibitor targeting the methyltransferases nsp14 and nsp16 of SARS-CoV-2. This compound, a derivative of Andrographolide, demonstrates significant antiviral activity with low toxicity, evidenced by a predicted LD50 of 700 mg/kg. It serves as a valuable research tool for studying SARS-CoV-2 replication and may contribute to therapeutic strategies against COVID-19. -
SARS-CoV-2 Main Protease Inhibitor
X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro), displaying an affinity with a Kd value of 0.057 μM. This compound effectively disrupts the proteolytic activity of Mpro, crucial for viral replication. X77 is primarily utilized in research applications aimed at understanding SARS-CoV-2 biology and developing antiviral therapeutics. -
SARS-CoV 3CLpro Inhibitor
GRL-0496 is a potent inhibitor of SARS-CoV 3CLpro, functioning through targeting the viral protease essential for replication. It demonstrates significant enzyme inhibition with an IC50 of 30 nM and exhibits antiviral activity with an EC50 of 6.9 μM against SARS-CoV. This compound is valuable for research into antiviral therapies and the development of inhibitors aimed at addressing coronavirus infections. -
SARS-CoV-2 3CLpro Inhibitor
CCF0058981 is a noncovalent inhibitor targeting the SARS-CoV-2 3CL protease (3CLpro), with an IC50 of 68 nM. This compound also demonstrates activity against the SARS-CoV-1 3CLpro, exhibiting an IC50 of 19 nM. CCF0058981 shows promising antiviral efficacy and is a valuable tool for research applications focused on COVID-19 and coronavirus protease inhibition. -
SARS-CoV-2 Mpro Inhibitor
TKB245 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating significant efficacy in preventing viral replication. This compound is effective in VeroE6 cells, making it a valuable tool for research on COVID-19 pathogenesis and therapeutics. Its role in protease inhibition provides insight into potential antiviral strategies against SARS-CoV-2. -
SARS-CoV-2 inhibitor
SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor that functions by inhibiting the SKP2 protein and stabilizing BECN1. With an EC50 value of 1 μM, this compound demonstrates significant antiviral activity against SARS-CoV-2. It is suitable for research applications focusing on viral pathogenesis and the development of therapeutic strategies targeting coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
CDD-1845 is a potent non-covalent, non-peptide inhibitor of SARS-CoV-2 main protease (Mpro) with a Ki of 3 nM. This compound effectively inhibits various Mpro variants, including ΔP168, A173V, and ΔP168/A173V. CDD-1845 is intended for research applications focused on SARS-CoV-2 protease inhibition and therapeutic development against COVID-19. -
SARS-CoV-2 Inhibitor
Kobophenol A is an oligomeric stilbene that acts as a SARS-CoV-2 inhibitor by hindering the interaction between the ACE2 receptor and the S1-RBD, exhibiting an IC50 value of 1.81 μM. This compound effectively blocks viral infection in cellular models, with an EC50 of 71.6 μM. Additionally, Kobophenol A demonstrates inhibitory activity against partially purified rat brain protein kinase C (PKC), with an IC50 of 52 µM, making it a valuable tool for studies on viral pathogenesis and enzyme regulation. -
SARS-CoV-2 Inhibitor
PAV-104 is an identified inhibitor of SARS-CoV-2, targeting the nucleocapsid (N) protein. By disrupting the oligomerization of the nucleocapsid, PAV-104 effectively interferes with viral particle assembly, thereby impeding replication at a multiplicity of infection (MOI) of 0.01. This compound is a valuable tool for research into antiviral strategies and the mechanistic understanding of SARS-CoV-2 propagation. -
SARS-CoV-2 Inhibitor
MAT-POS-e194df51-1 is an orally active non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 37 nM. This compound exhibits significant cytotoxicity, demonstrated by EC50 values of 64 nM in A549-ACE2-TMPRSS2 cells and 126 nM in HeLa-ACE2 cells. MAT-POS-e194df51-1 can be utilized in research focusing on antiviral drug development and the pathway exploration of SARS-CoV-2 infection mechanisms. -
SARS-CoV-2 Main Protease Inhibitor
(Rac)-X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro). It demonstrates strong binding affinity with a Kd value of 0.057 μM, making it valuable for research into antiviral strategies against SARS-CoV-2. This compound is useful for studying protease inhibition mechanisms and developing therapeutic interventions targeting viral replication. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-6 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 73 nM. This compound is critical for research focused on developing antiviral therapeutics against SARS-CoV-2 by targeting its main protease, which is essential for viral replication. Its efficacy makes it suitable for studies aimed at understanding the enzymatic mechanisms of the virus and the development of potential treatment strategies. -
SARS-CoV-2 3CL Protease Inhibitor
MK-7845 is a reversible covalent inhibitor targeting the 3CL protease of SARS-CoV-2, exhibiting an IC50 of 8.7 nM. This compound demonstrates potent antiviral activity, making it a valuable tool in the research of COVID-19 therapeutics. Its specificity for the 3CL protease supports investigations into the inhibition of viral replication and pathogenesis, facilitating the development of effective antiviral strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-14 is a potent inhibitor of SARS-CoV-2, exhibiting an IC50 of 0.39 μM. This compound is a niclosamide analogue, demonstrating enhanced stability in human plasma and liver S9 enzyme assays compared to niclosamide. Due to these properties, SARS-CoV-2-IN-14 may offer improved bioavailability and prolonged half-life when administered orally, making it a valuable tool for studying antiviral mechanisms and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
GRL-1720 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating an EC50 value of 15 µM. This compound exhibits significant anti-SARS-CoV-2 activity, making it a valuable tool for research related to coronavirus infection and therapeutics targeting viral replication. Its efficacy in inhibiting Mpro highlights its potential use in the development of antiviral strategies against SARS-CoV-2. -
HIV Protease Inhibitor
Palinavir is a potent inhibitor of HIV-1 and HIV-2 proteases, exhibiting an IC50 range of 0.5-30 nM. It demonstrates significant antiviral activity, making it valuable for research focused on HIV treatment strategies and drug development. Palinavir's mechanism of action targets the viral protease enzyme, disrupting the replication cycle of the virus and providing insights into HIV pathogenesis and therapeutic interventions. -
HIV-1 Protease Inhibitor
Lasinavir (CGP 61755) is a selective inhibitor of HIV-1 protease, exhibiting an IC50 value of 1 nM. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for studying HIV-1 infection and pathogenesis. Lasinavir is applicable in research focused on antiretroviral therapies and the mechanism of protease inhibition in viral replication. -
HIV Protease Inhibitor
L-689502 is a potent HIV protease inhibitor with an IC50 of 1 nM. This compound effectively disrupts the proteolytic activity of HIV-1 protease, thereby inhibiting viral replication. L-689502 is valuable for research into antiretroviral therapies and mechanisms of HIV resistance. -
Parasite Inhibitor
Betulonic acid, a naturally occurring triterpene, primarily targets parasite inhibition. It demonstrates significant antiparasitic activity along with anti-tumor and anti-inflammatory properties. Research applications include studies on its efficacy against various parasites, as well as exploration in cancer and inflammatory disease models. -
HSV Replication Inhibitor
Tromantadine hydrochloride is an antiviral agent that inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). As a derivative of Amantadine, it demonstrates significant antiherpetic activity and is primarily utilized in research applications focused on HSV pathogenesis and therapy development. This compound serves as a valuable tool in the study of viral infections and potential antiviral treatments. -
HSV Inhibitor
Isoborneol, a monoterpenoid alcohol, primarily targets herpes simplex virus type 1 (HSV-1) as a potent inhibitor. Exhibiting both antioxidant and antiviral properties, Isoborneol is utilized in research to explore its efficacy against viral infections. Its presence in the essential oils of various medicinal plants highlights its potential therapeutic applications in virology and pharmacology. -
HSV-1 Inhibitor
Soyasapogenol C is an oleanane-type triterpenoid that demonstrates significant antiviral activity against herpes simplex virus type 1 (HSV-1). With an IC50 value of 18.9 μM, it effectively inhibits viral replication, making it a valuable compound for research in virology and therapeutic development against HSV-1 infections. Its unique mechanism of action and biological potency position Soyasapogenol C as a candidate for further exploration in antiviral studies. -
HSV-1 Inhibitor
5-Nitrobarbituric acid functions as an inhibitor of herpes simplex virus type-1 (HSV-1), exhibiting an IC50 of 1.7 μM. This compound has demonstrated potential in virology research, particularly in studies aiming to understand and combat HSV-1 infections. Its utility in antiviral drug development positions it as a valuable tool for researchers exploring therapeutic strategies against herpes simplex viruses. -
HSV Inhibitor
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil is a nucleoside analogue that specifically targets herpes simplex virus (HSV). This compound exhibits potent antiviral activity by inhibiting viral replication. It is utilized in research focused on developing therapeutic strategies for HSV infections and studying viral pathogenesis. -
HSV Polymerases Inhibitor
PNU-183792 is a potent inhibitor of herpes simplex virus (HSV) polymerases, classified as a 4-oxo-dihydroquinoline. It demonstrates broad-spectrum antiviral activity, exhibiting IC50 values of 0.69 μM for human cytomegalovirus (HCM), 0.37 μM for varicella zoster virus, and 0.58 μM for HSV polymerases. Importantly, PNU-183792 operates selectively, showing no activity against human α, γ, or δ polymerases. Additionally, it exhibits inhibitory effects on simian varicella virus (SVV), murine cytomegalovirus (MCMV), and rat cytomegalovirus (RCMV), making it a valuable tool for antiviral research. -
HSV-1 Inhibitor
Leachianone G is an antiviral flavonoid derived from the root bark of Morus alba L., targeting herpes simplex virus type 1 (HSV-1). It exhibits significant antiviral activity, demonstrating an IC50 value of 1.6 μg/mL. This compound may be utilized in research focused on antiviral therapeutics and the mechanisms of HSV-1 infection.
